Trial
NCT03874325
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
AstraZeneca
Condition
Breast Cancer
Intervention
Durvalumab
Why stopped
lost funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-31